Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### Department of Health and Human Services

###### Food and Drug Administration

          - [Docket No. FDA-2010-N-0001]

# AGENCY:

Food and Drug Administration, HHS.

# ACTION:

Notice.

# SUMMARY:

                        The Food and Drug Administration (FDA) is announcing an amendment to the notice of a meeting of the Oncologic Drugs Advisory Committee. This meeting was announced in the                         **Federal Register**                         of October 19, 2010 (75 FR 64314). The amendment is being made to reflect changes in the                         *Date and Time, Agenda,*                         and                         *Procedure*                         portions of the document. We also are postponing a session regarding biologics license application (BLA) 125377, with the proposed trade name Yervoy (ipilimumab), manufactured by Bristol-Myers Squibb Co. The proposed indication (use) for this product is for the treatment of advanced melanoma in patients who have received prior therapy. This portion of the meeting has been postponed due to the need to complete the review of additional data submitted by the applicant. Future meeting dates may be announced in the                         **Federal Register.**

# FOR FURTHER INFORMATION CONTACT:

                        Nicole Vesely, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 31, Rm. 2417, Silver Spring, MD 20993-0002, 301-796-9001, FAX: 301-847-8533, e-mail:                         *Nicole.vesely@fda.hhs.gov,*                         or FDA Advisory Committee Information Line, 1-800-741-8138, 301-443-0572 in the Washington, DC area, code 301-451-2542. Please call the Information Line for up-to-date information on this meeting.                    

# SUPPLEMENTARY INFORMATION:

                    In the                     **Federal Register**                     of October 19, 2010 (75 FR 64314), FDA announced that a meeting of the Oncologic Drugs Advisory Committee would be held on December 2, 2010. On page 64314, in the first column, the                     *Date and Time*                     portion of the document is changed to read as follows:                

*Date and Time:*                     The meeting will be held on December 2, 2010, from 8 a.m. to 12:30 p.m.                

                    On page 64314, in the second column, the                     *Agenda*                     portion of the document is changed to read as follows:                

*Agenda:*                     On December 2, 2010, the committee will discuss new drug application (NDA) 022-405, with the proposed trade name Zictifa (vandetanib) Tablets, manufactured by iPR Pharmaceuticals, Inc., represented by AstraZeneca Pharmaceuticals LP (authorized U.S. agent). The proposed indication (use) for this product is for the treatment of patients with unresectable (non-operable) locally advanced or metastatic medullary thyroid cancer.                

                    On page 64314, in the second column, the third sentence in the                     *Procedure*                     portion of the document is changed to read as follows:                

*Procedure:*                     Oral presentations from the public will be scheduled between approximately 10:30 a.m. and 11:30 a.m.                

This notice is issued under the Federal Advisory Committee Act (5 U.S.C. app. 2) and 21 CFR part 14, relating to the advisory committees.

Dated: November 17, 2010.

Joanne Less,

Acting Associate Commissioner for Special Medical Programs.

[FR Doc. 2010-29522 Filed 11-22-10; 8:45 am]

BILLING CODE 4160-01-P